Skip to main content
. Author manuscript; available in PMC: 2012 Jul 10.
Published in final edited form as: Semin Nucl Med. 2011 Jan;41(1):29–44. doi: 10.1053/j.semnuclmed.2010.08.005

Table 4.

Other tracers used in clinical trials in prostate cancer 35,36,41,81,91-93,95

Tracer(s) Patient
number		 Disease stage Study
objective		 Sensitivity Specificity Year Group
11C-methionine, 18F-FDG 10 Advanced Staging NA NA 1999 Mascapinlac HA, et al
11C-methionine, 18F-FDG 12 Advanced Staging 72% (48%) NA 2002 Nunez R, et al.
11C-methionine 20 Early Staging 35% 47% 2005 Tooth G, et al
18F-FACBC 15 Advanced Staging,
restaging		 NA NA 2007 Schuster DM, et al.
18F-FDHT, 18F-FDG 7 Advanced Staging 78% (97%) NA 2004 Larson SM, et al.
18F-FDHT 20 Advanced Staging 63% NA 2005 Dehdasthi F, et al.
18F-fluoride 44 Bone metastases Staging 100% 100% 2006 Even-Sapir E, et al
18F-fluoride, 18F-FCH 38 Bone metastases Staging 81% (74%) 93% (99%) 2008 Beheshti M, et al